Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo



Status:Completed
Conditions:Psychiatric, Psychiatric, Eating Disorder
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:21 - 65
Updated:12/24/2017
Start Date:December 2014
End Date:September 2016

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
This study will test the effectiveness of the combination of Naltrexone and Bupropion
relative to placebo for reducing binge eating in persons with obesity and binge eating
disorder.


Inclusion Criteria:

- Binge eating disorder (full criteria as described in the American Psychiatric
Association Diagnostic and Statistical Manual of Mental Disorders, 5th edition)

- BMI between 30 kg/m2 and 50 kg/m2

- Not taking anti-depressant medications

- Read English proficiently enough to read study assessments

- Available for duration of treatment plus follow-up period

- Able to travel to study location (New Haven, CT) for monthly visits

- Agree to study procedures

Exclusion Criteria:

- Medical status judged by study physician as contraindication

- History of seizures

- Past or current anorexia nervosa, bulimia nervosa

- Current medications that influence eating/weight

- Current substance use disorder or other severe psychiatric disturbance (e.g.,
suicidality) that requires immediate treatment

- Pregnant or breastfeeding
We found this trial at
1
site
Yale School of Medicine
New Haven, Connecticut 06520
?
mi
from
New Haven, CT
Click here to add this to my saved trials